RNA binding motif single stranded interacting protein 3Genealiases: []
Q-omics provides the consensus-scored RBMS3 profile across patient tissues and cancer cell-line models. RBMS3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RBMS3 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, RBMS3 protein abundance shows 25,487 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, THCA, and LUAD as cancer lineages where RBMS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMS3 survival associations across molecular data types. RBMS3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMS3 RNA expression–survival associations across cancer types. High RBMS3 expression shows unfavorable associations in BLCA, MESO and CESC, but favorable associations in KIRC, UCS and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RBMS3 RNA expression.
This table summarizes RBMS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBMS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMS3 shows lower tumor expression in THCA, LUAD, COAD, UCEC, BLCA and LUSC. The THCA box plot shows higher RBMS3 RNA expression in normal versus tumor tissue (log2 FC = −0.956, t-test p < 0.001).
This table shows molecular features associated with RBMS3 in patient tissues and cancer cell lines. In patient samples, RBMS3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RBMS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
